Science is at the heart of cell and gene therapies, but business strategy is the lifeblood that ensures its survival and success. As a former healthcare provider and scientist with over 25 years of experience in biotechnology and pharmaceuticals, I learned early on that scientific breakthroughs alone do not guarantee market success. After transitioning into leadership roles, I realized that developing and executing the right business strategies is critical, particularly in a landscape like CGT where investment is scarce, competition is fierce, and failure is not an option. For innovation to shine in the real world, it must be paired with a robust understanding of business drivers, market needs, and strategic planning.
Since taking the lead at Likarda, my objective has been to fully harness the power of cutting-edge technology by aligning a thoughtful business strategy of encapsulating cells and delivering them effectively. The science is groundbreaking, but it was the revised strategic approach that realized the potential. By analyzing market trends, evaluating unmet needs, and taking a hard look at where resources and investments were headed, I began to see broader applications based on the versatility of the technology, which we positioned in cell therapies, biologics, small molecules, and even cryopreservation logistics. Diversifying our product pipeline also ensured that we weren’t dependent on a single market segment.
The key strategic pillars that every scientist or entrepreneur should embrace when venturing into the commercial world are:
Hypothesis generation is crucial in business strategy. You need to continually ask: “What do patients, clinicians, or industry leaders need that isn’t being met?” Understanding the broader healthcare ecosystem and identifying the true pain points is critical to shaping a product or technology that will stand out. For Likarda, a deep-dive into unmet needs led us to understand that our Core-Shell Spherification technology had the potential to disrupt multiple sectors.
Once you have proof-of-concept, it’s essential to ask “What else?” Expanding applications into new markets is a vital business strategy, especially when resources are limited. In the CGT space, funding often falls short. Having a diversified approach allows companies to build resilience.
Every entrepreneur needs to learn the language of finance. Knowing how to read a balance sheet, understanding capital efficiency, and projecting ROI are just as important as understanding the science behind your technology. Set realistic financial goals, secure the right funding partners, and deploy resources wisely.
A business model that works today might not work tomorrow. Whether it is regulatory shifts, technological advancements, or emerging competition, you must stay nimble. Be prepared to pivot to a platform play to avoid becoming a one-product company.
Every great scientific breakthrough must eventually commercialize to benefit society. Can you manufacture at scale? Can you deliver consistent results across different markets? Ensure you have the operational infrastructure in place and think about the path to commercialization early on.
Forming partnerships with larger corporations, academic institutions, or even competitors can help you scale faster and more efficiently. For instance, our collaboration with pharma companies and other partners allowed us to explore new pipelines while leveraging their expertise and resources.
In closing, successful leadership in the cell and gene therapy (CGT) space demands more than scientific acumen—it requires a fusion of visionary strategy and practical business insights. By knowing the market’s unmet needs, diversifying the applications of core technology, maintaining financial discipline, anticipating shifts, and forming strategic partnerships, we not only position our company to thrive but also ensure that the innovations we pioneer have the greatest possible impact on patients’ lives. These strategies collectively form a roadmap for bringing therapies to market that are not only groundbreaking in their science but sustainable in their execution. At the heart of all we do remains the ultimate goal: delivering transformative, life-improving solutions to patients worldwide. In this fast-paced and competitive landscape, it is this blend of science and strategy that will define the leaders of tomorrow.
By combining cutting-edge technology with strong business foundations, we don’t just aim to survive—we aim to shape the future of medicine.
This post was originally published on here
